Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07138196) titled 'A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease' on Aug. 11.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Qurient Co., Ltd.
Condition:
Chronic Graft-Versus-Host Disease
Intervention:
Drug: Adrixetinib
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: November 17, 2025
Target Sample Size: 18
Countries of Recruitment:
Spain
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07138196
Published by ...